AEST.MED.INT.HLD.SP.ADR/3 (3FMA) — Cash Flow Reinvestment Rate
AEST.MED.INT.HLD.SP.ADR/3 (3FMA) has a Cash Flow Reinvestment Rate of 0.39x as of December 2024, reinvesting €30.79 Million (capex €30.79 Million ) from operating cash flow of €79.67 Million. See AEST.MED.INT.HLD.SP.ADR/3 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
AEST.MED.INT.HLD.SP.ADR/3 Cash Flow Reinvestment Rate (2021–2024)
Historical reinvestment intensity for AEST.MED.INT.HLD.SP.ADR/3 across 3 annual periods. For the full cash flow conversion analysis, see AEST.MED.INT.HLD.SP.ADR/3 (3FMA) cash flow conversion.
Annual Cash Flow Reinvestment Rate for AEST.MED.INT.HLD.SP.ADR/3 (2021–2024)
Year-by-year capital reinvestment analysis for AEST.MED.INT.HLD.SP.ADR/3. See AEST.MED.INT.HLD.SP.ADR/3 leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.39x | €30.79 Million | €79.67 Million | €30.79 Million | ▼ -48.2% |
| 2023 | 0.75x | €55.46 Million | €74.29 Million | €55.46 Million | ▲ +14.1% |
| 2021 | 0.65x | €33.44 Million | €51.09 Million | €33.44 Million | — |